卡马替尼对CYP3A(咪达唑仑)和CYP1A2(咖啡因)底物药代动力学的影响
这项开放标签、多中心、单序列药物相互作用研究在MET异常实体瘤患者中评估卡马替尼对咪达唑仑和咖啡因暴露的影响。37例患者接受咪达唑仑2.5 mg与咖啡因100 mg双药鸡尾酒,卡马替尼400 mg每日两次连续给药后复测。结果显示卡马替尼为中度CYP1A2抑制剂,对咪达唑仑暴露无临床相关改变,安全性谱与已知一致。
要点
- 卡马替尼使咖啡因AUCinf升高134%、AUClast升高122%,提示其为中度CYP1A2抑制剂。
- 咪达唑仑Cmax升高22%,但被认为无临床意义,CYP3A底物暴露未见临床相关改变。
- 不良反应与卡马替尼已知安全性谱一致,未报告新的安全信号。
核心结论
- 卡马替尼是中度CYP1A2抑制剂,可使咖啡因暴露明显增加。
- 卡马替尼未引起咪达唑仑暴露的临床相关改变。
- 本研究未报告新的安全信号,不良事件与已知安全性谱一致。
研究设计与样本
- 开放标签、多中心、单序列药物相互作用研究,含分子预筛期、≤28天筛选/基线期和12天DDI期。
- DDI期第1天37例患者口服咪达唑仑2.5 mg与咖啡因100 mg双药鸡尾酒,第4天起卡马替尼400 mg每日两次连续给药,第9天复测。
- DDI期后患者按21天周期连续接受卡马替尼直至研究者判断疾病进展。
主要发现
- 与卡马替尼合用时咪达唑仑Cmax升高22%(90%CI 7-38%),被认为无临床意义。
- 咖啡因AUCinf升高134%(90%CI 108-163%),AUClast升高122%(90%CI 95-153%),Cmax无变化。
- 不良事件与卡马替尼已知安全性谱一致,未报告新安全信号。
关键数值与推荐
- 咪达唑仑Cmax升高22%(90%CI 7-38%),判为无临床意义。
- 咖啡因AUCinf升高134%(90%CI 108-163%),AUClast升高122%(90%CI 95-153%),Cmax无变化。
- 卡马替尼给药方案为400 mg每日两次连续给药。
临床怎么用
- 卡马替尼治疗期间合用CYP1A2敏感底物时需关注后者暴露升高带来的安全性风险。
- 合用CYP3A敏感底物(如咪达唑仑)时预计无需因暴露改变而调整。
- 仍需结合患者具体合并用药与不良反应监测进行个体化评估。
局限性
- 为开放标签、单序列设计,未设平行对照。
- 样本量37例,DDI评估限于咪达唑仑与咖啡因两种探针底物。
- 摘要未报告长期随访中CYP1A2抑制相关的临床结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preclinical studies showed that capmatinib reversibly inhibits cytochrome P450 (CYP) 3A4 and CYP1A2 in a time-dependent manner. In this study, we evaluated the effect of capmatinib on the exposure of sensitive substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with mesenchymal-epithelial transition (MET)-dysregulated solid tumours. Besides pharmacokinetics, we assessed treatment response and safety. METHODS: This open-label, multicentre, single-sequence study consisted of a molecular prescreening period, a screening/baseline period of ≤28 days and a drug-drug interaction (DDI) phase of 12 days. On day 1 of the DDI phase, 37 patients received a single oral dose of midazolam 2.5 mg and caffeine 100 mg as a two-drug cocktail. Capmatinib 400 mg bid was administered from day 4 on a continuous dosing schedule. On day 9 of the DDI phase, patients were re-exposed to midazolam and caffeine. After the DDI phase, patients received capmatinib on continuous 21-day cycles until disease progression at the discretion of the investigator. RESULTS: A 22% (90% confidence interval [CI] 7-38%) increase in the midazolam maximum plasma concentration (Cmax ) was noted when administered with capmatinib, but this was deemed not clinically meaningful. Co-administration with capmatinib resulted in 134% (90% CI 108-163%) and 122% (90% CI 95-153%) increases in the caffeine area under the plasma concentration-time curve from time zero to infinity (AUCinf ) and area under the plasma concentration-time curve from time zero to the last measurable point (AUClast ), respectively, with no change in Cmax . Adverse events were consistent with the known capmatinib safety profile. No new safety signals were reported in this study. CONCLUSION: The data from this study demonstrated that capmatinib is a moderate CYP1A2 inhibitor. Capmatinib administration did not cause any clinically relevant changes in midazolam exposure.
引用
- Chen X, Isambert N, López-López R, et al. Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours. Br J Clin Pharmacol. 2022. PMID: 36131603. doi:10.1111/bcp.15544
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。